Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 9/20 | 0.75 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.75 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.73 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.73 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.73 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.73 |
| ▸ | LDHA | P00338 | 1/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
| ▸ | FBP1 | P09467 | 1/20 | 0.73 |
| ▸ | SRC | P12931 | 1/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.73 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.73 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26067680 | 1.00 | DNPH1 (0.75) | DNPH1TAS1R3TAS1R1ADORA1P2RY1 | |
| SCHEMBL30004415 | 1.00 | DNPH1 (0.75) | DNPH1TAS1R3TAS1R1ADORA1P2RY1 | |
| SCHEMBL14358309 | 0.99 | DNPH1 (0.74) | DNPH1TAS1R3TAS1R1ADORA1P2RY1 | |
| SCHEMBL26067558 | 0.93 | DNPH1 (0.66) | DNPH1TAS1R3TAS1R1ADORA1P2RY1 | |
| SCHEMBL26067580 | 0.93 | DNPH1 (0.66) | DNPH1TAS1R3TAS1R1ADORA1P2RY1 | |
| SCHEMBL31396265 | 0.92 | P2RX3 (0.77) | DNPH1TAS1R3TAS1R1P2RY1TRPM2 | |
| SCHEMBL14358316 | 0.92 | ADORA1 (0.77) | DNPH1TAS1R3TAS1R1ADORA1P2RY1 | |
| SCHEMBL18574268 | 0.92 | P2RY1 (0.66) | DNPH1TAS1R3TAS1R1ADORA1P2RY1 | |
| SCHEMBL14929511 | 0.92 | P2RY1 (0.66) | DNPH1TAS1R3TAS1R1ADORA1P2RY1 | |
| SCHEMBL14946362 | 0.92 | P2RY1 (0.66) | DNPH1TAS1R3TAS1R1ADORA1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185100-B2 | Methods for modulating taste receptors | MARS, INCORPORATED (US) | 2021-11-30 | — | — | US | claimed |
| US-20140296167-A1 | GLYCOSYLATION SITE-SPECIFIC ANTIBODIES AND ANTI-CANCER COMPOUNDS | DETROIT R&D, INC. | 2014-10-02 | — | — | US | claimed |
| US-12214347-B2 | Nanopore/nanowell electrode enabled exonuclease sequencing | ELECTRONIC BIOSCIENCES, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240287516-A1 | COMPOSITIONS AND METHODS OF USE FOR MUTATED HOTAIR IN THE TREATMENT OF CANCERS | UNITED STATES GOVERNMENT | 2024-08-29 | — | — | US | disclosed |
| EP-4403042-A2 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | Mars, Incorporated (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-3229612-B1 | USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230405580-A1 | NANOPORE/NANOWELL ELECTRODE ENABLED EXONUCLEASE SEQUENCING | ELECTRONIC BIOSCIENCES INC (US) | 2023-12-21 | — | — | US | disclosed |
| EP-4283285-A2 | NANOPORE/NANOWELL ELECTRODE ENABLED EXONUCLEASE SEQUENCING | Electronic Biosciences Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-4026916-B1 | NANOPORE/NANOWELL ELECTRODE ENABLED EXONUCLEASE SEQUENCING | ELECTRONIC BIOSCIENCES INC (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11752497-B2 | Nanopore/nanowell electrode enabled exonuclease sequencing | ELECTRONIC BIOSCIENCES, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11685923-B2 | Methods of enhancing translation ability of RNA molecules, treatments, and kits | CORNELL UNIVERSITY (US) | 2023-06-27 | — | — | US | disclosed |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2016094702-A2 | METHODS FOR MODULATING TASTE RECEPTORS | MARS, INCORPORATED (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094690-A1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| US-20140296167-A1 | GLYCOSYLATION SITE-SPECIFIC ANTIBODIES AND ANTI-CANCER COMPOUNDS | DETROIT R&D, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140107189-A1 | MODIFIED POLYNUCLEOTIDES ENCODING APOPTOSIS INDUCING FACTOR 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140010861-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | modeRNA Therapeutics (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130266640-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. | 2013-10-10 | — | — | US | disclosed |
| WO-2009127230-A1 | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION | CUREVAC GMBH (DE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | DNPH1 1736/4885TAS1R3 1881/4885TAS1R1 2333/4885 |
| US-20130266640-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | DNPH1 1229/4885TAS1R3 4333/4885TAS1R1 4149/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | DNPH1 1736/4885TAS1R3 1881/4885TAS1R1 2333/4885 |
| US-20140010861-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | DNPH1 2948/4885TAS1R3 3866/4885TAS1R1 3712/4885 |
| US-20140107189-A1 | MODIFIED POLYNUCLEOTIDES ENCODING APOPTOSIS INDUCING FACTOR 1 | MSH2, APAF1, MCL1 | DNPH1 3739/4885TAS1R3 2745/4885TAS1R1 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.